(R)-2-(tert-butylthio)-5-chloro-6-(2-methylpiperazin-1-yl)-1H-benzo[d]imidazole | 1170735-52-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (R)-2-(tert-butylthio)-5-chloro-6-(2-methylpiperazin-1-yl)-1H-benzo[d]imidazole
• CAS: 1170735-52-0
• 化学式: C₁₆H₂₃ClN₄S
• 分子量: 338.904
• InChiKey: JUSLJFAVUZIAMR-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.91
• 重原子数：
  22.0
• 可旋转键数：
  2.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  43.95
• 氢给体数：
  2.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  (R)-2-(tert-butylthio)-5-chloro-6-(2-methylpiperazin-1-yl)-1H-benzo[d]imidazole 、 乙醛 在 Zn(BH3CN)2 作用下， 以 甲醇 为溶剂， 以70%的产率得到2-tert-butylsulfanyl-6-chloro-5-[(2R)-4-ethyl-2-methylpiperazin-1-yl]-1H-benzimidazole
  参考文献：
  名称：

  Optimization of benzimidazole series as opioid receptor-like 1 (ORL1) antagonists: SAR study directed toward improvement of selectivity over hERG activity

  摘要：

  A structure-activity relationship (SAR) study on the benzimidazole series of opioid receptor-like 1 (ORL1) antagonists related to 1 is described. Optimization of 1 by introduction of a hydrophilic substituent into the thioether part resulted in identification of potent ORL1 antagonists with high selectivity over binding affinity for hERG and other opioid receptors. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.022
• 作为产物：
  描述：

  tert-butyl (R)-4-(6-chloro-2-thioxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-3-methylpiperazine-1-carboxylate 、 叔丁醇 在 三氟乙酸 作用下， 以94%的产率得到(R)-2-(tert-butylthio)-5-chloro-6-(2-methylpiperazin-1-yl)-1H-benzo[d]imidazole
  参考文献：
  名称：

  Optimization of benzimidazole series as opioid receptor-like 1 (ORL1) antagonists: SAR study directed toward improvement of selectivity over hERG activity

  摘要：

  A structure-activity relationship (SAR) study on the benzimidazole series of opioid receptor-like 1 (ORL1) antagonists related to 1 is described. Optimization of 1 by introduction of a hydrophilic substituent into the thioether part resulted in identification of potent ORL1 antagonists with high selectivity over binding affinity for hERG and other opioid receptors. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.022